Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.35 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.35 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their drug candidates. They acknowledged the challenges but emphasized their commitment to innovation.
Management highlighted ongoing efforts in drug development.
They expressed confidence in the pipeline despite the EPS loss.
Despite a loss in EPS, Crinetics Pharmaceuticals saw a positive stock reaction, rising 4.34%. This increase may reflect investor optimism about the company's drug development efforts. The lack of revenue figures and guidance leaves some uncertainty, but management's focus on their pipeline could be encouraging for future growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ZTO EXPRESS CAYMAN I Class A ADR
Mar 12, 2019